Treatment Trials

2 Clinical Trials for Various Conditions

Focus your search

      RECRUITING
      Genetic Testing in Guiding Treatment for Patients With Brain Metastases
      Description

      This phase II trial studies how well genetic testing works in guiding treatment for patients with solid tumors that have spread to the brain. Several genes have been found to be altered or mutated in brain metastases such as NTRK, ROS1, CDK, PI3K, or KRAS G12C. Medications that target these genes such as abemaciclib, paxalisib, entrectinib and adagrasib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Genetic testing may help doctors tailor treatment for each mutation.

      Conditions
      CDK Gene MutationMetastatic Malignant Neoplasm in the BrainMetastatic Malignant Solid NeoplasmNTRK Family Gene MutationPI3K Gene MutationROS1 Gene MutationKRAS G12C Mutation
      Talk to us
      NOT_YET_RECRUITING
      A Phase 1/2 Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors
      Description

      This study, the first clinical trial of AVZO-023, aims to determine the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-023 in patients with advanced solid tumors. AVZO-023 is an oral medication that inhibits cyclin-dependent kinase 4 (CDK4).

      Conditions
      Advanced Solid TumorHR+/HER2- Breast CancerHR+, HER2-, Advanced Breast CancerCDK Gene MutationCCND1 Gene AmplificationCDK4 Gene Amplification
      Talk to us